About us Get involved Research COVAX Marketplace News & stories Careers Contact A global coalition for a global problem Epidemic diseases affect us all. They do not respect borders. CEPI is a innovative global partnership between public, private, philanthropic, and civil society organisations. We're working together to accelerate the development of vaccines against emerging infectious diseases and enable equitable access to these vaccines for people during outbreaks. THE CEPI TEAM Leadership Our Leadership Team works across our three offices in Oslo, London and Washington D.C. Astrid Helgeland Director of Human Resources Biography Frederik Kristensen Deputy CEO and Director of People, Planning and Policy Biography Luc Debruyne Strategic Advisor to the CEO Biography Mads Høgholen Director of Finance and Operations Biography Melanie Saville Director of Vaccine Research & Development Biography Nicole Lurie US Director and Strategic Advisor to the CEO Rachel Grant Director of Communications and Advocacy Biography Richard Hatchett Chief Executive Officer Biography Richard Wilder General Counsel and Director of Business Development Biography Samia Saad Director of Resource Mobilisation & Investor Relations Biography Board CEPI is a Norwegian Association. The primary governing body is the Board, which has 12 voting members (four investors and eight independent members representing competencies including industry, global health, science, resource mobilisation, finance) and five observers. The Board is advised on decisions, such as prioritising pathogens and selecting development partners, by our Scientific Advisory Committee. Board Committees We have four Board Committees: Executive and Investment, Nominations, Compensation, Diversity and Inclusion, Audit and Risk, and Equitable Access, with members of our Board Committees listed below. Other Board members or experts may be called upon as advisers or observers as needed. Voting members Charlotte Watts Chief Scientific Advisor & Director of Research and Evidence Division, UK Foreign, Commonwealth & Development Office Biography Cherry Gagandeep Kang Christian Medical College Vellore Biography David Reddy Medicines for Malaria Venture Biography Dr. Nísia Trindade Lima President of Oswaldo Cruz Foundation (Fiocruz), Brazil Biography Ichiro Kurane Former Director General, National Institute of Infectious Diseases, Japan Biography Jane Halton Chair Biography Jeremy Farrar Director of the Wellcome Trust Biography John Nkengasong Africa Centers for Disease Control and Prevention Nadine Gbossa Regional Director, West and Central Africa, International Fund for Agricultural Development Biography Peter Piot Biography Rajeev Venkayya Vaccine Business Unit, Takeda Pharmaceutical Company Limited Biography Veronika von Messling Federal Ministry of Education and Research, Germany Biography Non-voting members Dr. Juan Pablo Uribe World Bank as Global Director for Health, Nutrition and Population and Director of the Global Financing Facility for Women, Children and Adolescents Biography Helen Rees Wits Reproductive Health and HIV Institute, University of the Witwatersrand (Chair of CEPI Scientific Advisory Committee) Biography Peggy Hamburg American Association for the Advancement of Science (Chair of CEPI Joint Coordination Group) Richard Hatchett Chief Executive Officer Biography Soumya Swaminathan World Health Organization CEPI Board Committees Executive and Investment Cherry Gagandeep Kang Christian Medical College Vellore David Reddy Medicines for Malaria Venture Jane Halton Chair Jeremy Farrar Director of the Wellcome Trust Nominations, Compensation, Diversity and Inclusion Charlotte Watts Chief Scientific Advisor & Director of Research and Evidence Division, UK Foreign, Commonwealth & Development Office Nadine Gbossa Regional Director, West and Central Africa, International Fund for Agricultural Development Rajeev Venkayya Vaccine Business Unit, Takeda Pharmaceutical Company Limited Veronika von Messling Federal Ministry of Education and Research, Germany Audit and Risk Alex Cebotari (non-voting member) World Bank Ichiro Kurane Former Director General, National Institute of Infectious Diseases, Japan Peter Piot Equitable Access Charlotte Watts UK Department for International Development Cherry Gagandeep Kang Professor Wellcome Trust Research Laboratory Division of Gastrointestinal Sciences Christian Medical College, Vellore David Reddy Medicines for Malaria Venture John Nkengasong Africa Centers for Disease Control and Prevention Soumya Swaminathan (non-voting member) World Health Organization Investors & Partners CEPI was founded in Davos by the governments of Norway and India, the Bill & Melinda Gates Foundation, Wellcome, and the World Economic Forum. To date, CEPI has secured financial support from Australia, Austria, Belgium, the Bill & Melinda Gates Foundation, Canada, Denmark, the European Commission, Ethiopia, Finland, Germany, Hungary, Iceland, Indonesia, Italy, Japan, Kuwait, Lithuania, Luxembourg, Malaysia, Mexico, Netherlands, New Zealand, Norway, Panama, Romania, Saudi Arabia, Serbia, Singapore, Switzerland, The Republic of Korea, United Kingdom, USAID, and Wellcome. Additionally, CEPI has also received support from private sector entities as well as public contributions through the UN Foundation COVID-19 Solidarity Response Fund. Close collaboration with our partners is crucial for the success of our work. INVEST NOW Investors Council All investors contributing to CEPI’s funding pool are invited to join our Investors Council. The council nominates Investor representatives to the Board and has some rights including approval any single investments over $100 m. Each investor appoints one person to represent them on the Investors Council, serving as members for the duration of their pledged commitment. The Investors Council receives regular updates from the CEPI team, shares information with CEPI and each other, provides guidance and oversight of CEPI activities, and engages in resource mobilisation efforts. Four members of the CEPI Investors Council serve on the CEPI Board. CEPI launches at 2017 Davos Meeting TERMS OF REFERENCE Scientific Advisory Committee The Scientific Advisory Committee is an independent body within the CEPI governing structure that provides world-class scientific support, advice, and guidance to CEPI staff and the CEPI Board in responding to the current COVID-19 pandemic. They will also deliver guidance and challenge towards CEPI’s US$3.5bn plan, announced in March 2021, to mitigate or even dramatically reduce the threat of future pandemics and epidemics. Final decision-making about the issues addressed by the committee rests with CEPI staff or the Board. TERMS OF REFERENCE Members of the Scientific Advisory Committee Alan D. Barrett Sealy Institute for Vaccine Sciences, University of Texas Medical Branch Alash’le Abimiku Institute of Human Virology, Nigeria Azra Ghani Imperial College London, UK Christian Drosten Institute of Virology, Charité – Universitätsmedizin Berlin, Germany Dominique Maugeais Consultant Frances Priddy Vaccine Alliance Aotearoa New Zealand, Malaghan Institute of Medical Research Gary Nabel Modex Therapeutics George Gao Chinese Center for Disease Control and Prevention Helen Rees Wits Reproductive Health and HIV Institute, University of the Witwatersrand (Chair of CEPI Scientific Advisory Committee) Inger Damon Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, USA Josie Golding Wellcome Ken J. Ishii International Research and Development Center for Mucosal Vaccines, The Institute of Medical Science, The University of Tokyo Kent Kester Translational Science & Biomarkers, Sanofi Pasteur Laura Palomares Instituto de Biotecnología, Universidad Nacional Autónoma de México (UNAM) Linfa Wang Duke-NUS Medical School, Singapore Luciana Borio Council on Foreign Relations Mahmudur Rahman Consultant Marc Lipsitch Harvard T.H. Chan School of Public Health, USA Marco Safadi Department of Pediatrics, Santa Casa de Sao Paulo School of Medical Sciences, Brazil Michael King Consultant (SAC Vice Chair) Michael Watson MEVOX & VaxEquity Ltd. Michel De Wilde MDW Consultant, LLC Paula Bryant Office of Biodefense, Translational Research, and Research Resources, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA Peter Dull Integrated Clinical Vaccine Development, Vaccine Development & Surveillance, Bill & Melinda Gates Foundation Peter Paradiso Paradiso Biologics Consulting LLC Peter Smith London School of Hygiene & Tropical Medicine Phil Krause US Food and Drug Administration Rebecca Grais Epicentre Rino Rappuoli GSK Vaccines Sani Aliyu Nigeria Presidential Task Force on COVID-19, Federal Government of Nigeria Stanley Plotkin Emeritus Professor, University of Pennsylvania, USA Stephen Thomas Institute for Global Health and Translational Sciences, SUNY Upstate Medical University, USA V. Krishna Mohan Bharat Biotech, India Vaseeharan Sathiyamoorthy World Health Organization Vineeta Bal Indian Institute of Science Education and Research, Pune, India Joint Coordination Group Our Joint Coordination Group is a roundtable of independent institutions with an interest in seeing CEPI’s vaccines successfully developed and deployed in an outbreak. These independent institutions play a role in various elements of the vaccine development lifecycle, from vaccine research and development all the way through to deploying vaccines during an outbreak. Members of our Joint Coordination Group come together to discuss how we can best enhance our efforts to deliver and deploy vaccines by addressing challenges related to the research and development, regulation, stockpiling, and delivery of these products. In particular, while the group focuses on advancing our vaccine portfolio, its work also informs the broader field of vaccine development and preparedness. Members also have a role in planning for rapid response to a priority pathogen or an unknown pathogen. Our Joint Coordination Group consists of 10 to 15 member organisations, which in turn appoint individuals to represent them at meetings. From time to time, the group may choose to invite other organisations and experts to participate in meetings. The current members of the Joint Coordination Group include: WHO, GAVI, EMA, FDA, MSF, UNICEF, IFRC, AVAREF, NIBSC, and Wellcome. TERMS OF REFERENCE CEPI’s commitment to tackling racism A destructive legacy of racism has led to deeply entrenched implicit biases and institutional racism, which have hurt countless people for generations. These inequalities are widespread and, as we have seen in the current COVID-19 pandemic, have led to stark inequities in access to healthcare and poorer health outcomes for affected communities globally. Tackling this inequality is core to CEPI’s mission to ensure fair access to all the vaccines we develop. Through our strategic partnerships in countries around the world we also seek to build vaccine Research & Development capacity, strengthen domestic expertise, and nurture scientific talent. In response to COVID-19, we’ve launched the COVID-19 Vaccine Global Access (COVAX) initiative, in partnership with the World Health Organization (WHO) and Gavi, to ensure equitable access to COVID-19 vaccines for all countries, at all levels of development. We are also committed to affecting positive change in the workplace and the principles of equality, inclusion, and non-discrimination guide all our internal and external policies. CEPI is a young organisation, launched in 2017, and our aim from the outset has been to build a diverse and inclusive organisation that reflects the populations we serve. We are proud to say that one in five of the CEPI team now come from low-income or middle-income countries and over half are women. We also recognise that our executive leadership team does not reflect this diversity and our aim is to ensure we develop and implement a comprehensive plan to ensure that this goal of diversity at all levels is achieved over time. CEPI is a global coalition comprising members and representatives from all continents. We value the substantial geographical and cultural diversity of our partners and we welcome dialogue with them about the issue of racism and how we, as a coalition, can combat its negative effects. We are determined to play our role in helping to overcome the challenges presented by institutional bias and discrimination. We accept that this won’t be easy and that we are not perfect, but we will persevere. CEPI believes positive and long-lasting change can only be achieved by learning from each other’s experiences and through collective action. A coalition by design, we will always stand together with our staff, our partners, and the communities that we serve around the world to push back against racism in all its forms. Anti-Slavery and Human Trafficking Statement At CEPI we oppose modern slavery in all its forms, and we are committed to ensuring that there is no slavery or human trafficking in our operations or our supply chain. We are committed to improving our practices to combat slavery and human trafficking. Our full statement is available to read here. LEADERSHIP BOARD INVESTORS & PARTNERS SCIENTIFIC ADVISORY COMMITTEE JOINT COORDINATION GROUP CEPI’S COMMITMENT TO TACKLING RACISM ANTI-SLAVERY AND HUMAN TRAFFICKING STATEMENT ABOUT US Why we exist Mission Approach Who we are Overview Leadership Board Investors & Partners Scientific Advisory Committee Joint Coordination Group Antiracism statement Anti-Slavery Statement Governance Articles of association Board Meeting Summaries Board of Directors' report, annual accounts and Auditor's statement Business Plan CEPI Policies Equitable Access Financial Internal policies Investors Council Joint Coordination Group Members Meetings Other Guidance for Awardees Scientific Advisory Committee Strategy & Progress Terms of reference GET INVOLVED Support CEPI Invest in CEPI Progress Work with CEPI Work at CEPI Follow our work Calls for Proposals RESEARCH & DEVELOPMENT Our portfolio Platform Technology Priority diseases MERS Lassa Nipah Disease X Rift Valley fever Chikungunya Ebola Vaccine science Biological Standards, Assays & Animal Models Collect vaccine data Researching emerging infectious diseases INFO & ACTION News & stories Outbreaks Careers Contact Social LinkedIn Twitter Legal Terms of use Privacy policy Procurement tenders Reporting Concern ©2021 CEPI. All rights reserved